98%
921
2 minutes
20
The advancement of biopharmaceutical manufacturing, particularly continuous processing, has heightened the need for next-generation analytical tools approaching real-time monitoring of critical quality attributes (CQAs) and process parameters (CPPs). Current methods, primarily offline and labor-intensive, fail at delivering analytical information that can be used for process analytical technology (PAT) to control and optimize the manufacturing process, while also lacking the ability of multi-attribute monitoring, thus requiring a large number of samples (or sampling amount) to be collected. This work introduces the concept of PAT-on-a-chip, consisting of an integrated microfluidic platform designed to perform at-line analysis and characterization of cell culture samples in the context of monoclonal antibody (mAb) production. Specifically, a sample preparation-free miniaturized lectin-based assay was developed to measure levels of high mannose glycans and integrated with affinity-based assays to measure mAb titers and key impurities, namely Chinese hamster ovary (CHO) host cell proteins (HCP), within the same chip, resorting to a common colorimetric readout. The microfluidic chips were operated in a customized and integrated instrument comprising miniaturized photodiodes, connected to a graphical user interface for data recording and signal quantification. The PAT-on-a-chip unit allowed to achieve fit-for-purpose analyte quantification, while offering performance comparable to state-of-the-art offline analytical methods (Pearson R > 0.93), namely capillary electrophoresis with laser-induced fluorescence (CE-LIF) for glycan analysis, well plate immunoassays for CHO HCP and protein A HPLC for mAb titers, thus validating its potential to expand the modern PAT toolbox.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bios.2025.117625 | DOI Listing |
Bioprocess Biosyst Eng
August 2025
Department of Sustainable Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, 73019, USA.
The demand to accelerate monoclonal antibody (mAbs) process development timelines using Chinese hamster ovary (CHO) host cells to bring therapies to patients sooner is gaining momentum. The applicability of single use high-throughput (HTP) bioreactor system such as Ambr250 facilitating precise and automated control is very promising. This entails optimizing process parameters through design of experiments (DoE) using less resources and time, compared to traditionally employed large-scale bench top reactors (2-5L).
View Article and Find Full Text PDFSheng Wu Gong Cheng Xue Bao
August 2025
Henan Bioengineering Technology Research Center, Zhengzhou 450010, Henan, China.
Hemoglobin A1c (HbA1c) has a unique structure that makes monoclonal antibody (mAb) preparation challenging. This study aims to develop a method for preparing HbA1c mAbs and establish a fluorescent immunochromatographic assay (FICA) for rapid detection of HbA1c. Three glycosylated peptides were synthesized and used to prepare complete antigens, which were identified by dot enzyme-linked immunosorbent assay (Dot-ELISA) and ultraviolet absorption spectroscopy.
View Article and Find Full Text PDFMembranes (Basel)
August 2025
Department of Chemical Engineering, The Pennsylvania State University, University Park, PA 16802, USA.
Background: Recent advances in cell culture have led to significant increases in monoclonal antibody (mAb) titers, opening a new window of opportunity for developing a fully continuous downstream purification process based on the selective precipitation of the mAb from harvested cell culture fluid, with the precipitate dewatered and washed using single-pass tangential flow filtration (SPTFF) with microfiltration membranes.
Methods: Experiments were performed with precipitates of human serum immunoglobulin G formed using ZnCl and polyethylene glycol, both with and without added disodium malonate. SPTFF was conducted in both hollow fiber and screened cassette modules, with the critical flux identified using flux-stepping experiments.
Biologicals
August 2025
Synermore Biologics (Suzhou) Co., Ltd., Suzhou, China. Electronic address:
Objective: To compare rabies virus neutralizing antibody (RVNA) kinetics and safety profiles of Zamerovimab and Mazorelvimab monoclonal antibodies (mAbs) versus human rabies immunoglobulin (HRIG) in Category III rabies-exposed patients with heterogeneous wound characteristics.
Methods: In this randomized, double-blind, phase III trial, 1000 participants with Category III exposure were stratified into single-wound (n = 735) and multi-wound (n = 265) subgroups. Subjects received either 0.
NPJ Vaccines
August 2025
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
VRC01-class antibodies are a genetically restricted class of antibodies capable of potently neutralizing diverse strains of HIV-1. Unmutated VRC01 precursors fail to recognize recombinant HIV-1 Envelope (Env) proteins, which necessitated the development of germline targeting vaccine immunogens capable of initiating VRC01-class B cell response. Among these, we developed an anti-idiotypic monoclonal antibody (ai-mAb)-derived VRC01 class targeting immunogen.
View Article and Find Full Text PDF